Recently, Pazopanib, first proposed as a multi-target inhibitor of VEGFR1/2/3, PDGFR, FGFR, c-KIT and c-Fms and approved for the treatment of advanced renal cell carcinoma, and Ponatinib, first described as Pan-Bcr-Abl tyrosine kinase inhibitor and approved for the treatment of chronic myeloid leukemia, were both reported as necroptosis inhibitors at the submicromolar range,33 the former blocking mainly RIPK1 and the second blocking both RIPK1 and RIPK3. Here, RIPK3 is linked to renal cell carcinoma.